Mutating a flexible region of the RSV F protein can stabilize the prefusion conformation

Science. 2024 Sep 27;385(6716):1484-1491. doi: 10.1126/science.adp2362. Epub 2024 Sep 26.

Abstract

The respiratory syncytial virus (RSV) fusion (F) glycoprotein is highly immunogenic in its prefusion (pre-F) conformation. However, the protein is unstable, and its conformation must be stabilized for it to function effectively as an immunogen in vaccines. We present a mutagenesis strategy to arrest the RSV F protein in its pre-F state by blocking localized changes in protein structure that accompany large-scale conformational rearrangements. We generated a series of mutants and screened them in vitro to assess their potential for forming a stable pre-F. In animals, the immunogenicity of a representative mutant F protein, with a conformation confirmed by cryo-electron microscopy, elicited levels of neutralizing antibodies and protection against RSV-induced lung damage that were comparable to those of DS-Cav1, a pre-F used in a licensed vaccine.

MeSH terms

  • Animals
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / immunology
  • Cryoelectron Microscopy
  • Humans
  • Immunogenicity, Vaccine
  • Lung / virology
  • Mice
  • Mice, Inbred BALB C
  • Mutagenesis
  • Mutation
  • Protein Conformation
  • Protein Stability
  • Respiratory Syncytial Virus Infections* / immunology
  • Respiratory Syncytial Virus Infections* / prevention & control
  • Respiratory Syncytial Virus Vaccines* / chemistry
  • Respiratory Syncytial Virus Vaccines* / genetics
  • Respiratory Syncytial Virus Vaccines* / immunology
  • Respiratory Syncytial Virus, Human* / genetics
  • Respiratory Syncytial Virus, Human* / immunology
  • Viral Fusion Proteins* / chemistry
  • Viral Fusion Proteins* / genetics
  • Viral Fusion Proteins* / immunology

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • F protein, human respiratory syncytial virus
  • Respiratory Syncytial Virus Vaccines
  • Viral Fusion Proteins